Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases

Ishikawa, Kiyohito; Hamasuna, Ryoichi; Uehara, Shuichiro; Yasuda, Mitsuru; Yamamoto, Shingo; Hayami, Hiroshi; Takahashi, Satoshi; Matsumoto, Tetsuro; Minamitani, Shinichi; Kadota, Jun Ichi; Iwata, Satoshi; Kaku, Mitsuo; Watanabe, Akira; Sunakawa, Keisuke; Sato, Junko; Hanaki, Hideaki; Tsukamoto, Taiji; Kiyota, Hiroshi; Egawa, Shin; Deguchi, Takashi; Matsumoto, Minori; Tanaka, Kazushi; Arakawa, Soichi; Fujisawa, Masato; Kumon, Hiromi; Kobayashi, Kanao; Matsubara, Akio; Wakeda, Hironobu; Amemoto, Yoshinosuke; Onodera, Satoshi; Goto, Hirokazu; Komeda, Hisao; Yamashita, Masuo; Takenaka, Tadasu; Fujimoto, Yoshinori; Tsugawa, Masaya; Takahashi, Yūzō; Maéda, Hiroshi; Onishi, Hideaki; Ishitoya, Satoshi; Nishimura, Kazuo; Mitsumori, Kenji; Ito, Toru; Togo, Yoshikazu; Nakamura, Ichiro; Ito, Noriyuki; Kanamaru, Sojun; Hirose, Takaoki; Mizutani, Takashi; Yamada, Daisuke; Ishihara, Satoshi; Oka, Hideyuki; Inatomi, Hisato; Matsui, Takashi; Kobuke, Makoto; Kunishima, Yasuharu; Kimura, Takahiro; Ichikawa, Takaharu; Kagara, Ichiro; Matsukawa, Masanori; Takahashi, Koichi; Mita, Koji; Katô, Masao; Okumura, Kazuhiro; Kawanishi, Hiroaki; Hashimura, Takayuki; Aoyama, Teruyoshi; Shigeta, Masanobu; Koda, Shuntaro; Taguchi, Keisuke; Matsuda, Y.

doi:10.1016/j.jiac.2015.05.014

Cited by 28 publications

(14 citation statements)

References 19 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the susceptibility of our urine isolates was 79.3% to cefotaxime (92.8% in USA), 85.7% to cefepime (94% in U.S.A., and 97.7% in Japan), 84.4% for piperacillin-tazobactam (91% in U.S.A., and 97.7% in Japan), and 73.0% for ciprofloxacin (91.6% in U.S.A., 77.3% in Korea, and 91.7% in Japan. )232425.…”

Section: Discussionmentioning

confidence: 99%

The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis

Lin

Wang

Chang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Drug-resistant Klebsiella pneumoniae, especially extended-spectrum β-lactamase (ESBL)- and/or AmpC β-lactamase-producing strains, is an emerging problem worldwide. However, few data focusing on drug susceptibility of K. pneumoniae from community is available. In this study, we analyzed 1016 K. pneumoniae isolates from outpatients or those visiting emergency rooms collected during 2002–2012 from Taiwan Surveillance of Antimicrobial Resistance program. Significantly decreased susceptibilities to 3rd generation cephalosporins and ciprofloxacin were found during the study period. By 2012, susceptibility to cefotaxime and ciprofloxacin was 83.6% and 81.6%, respectively. The prevalence of ESBL-producers increased from 4.8% in 2002 to 11.9% in 2012 (P = 0.012), while that of AmpC β-lactamase-producers increased from 0% to 9.5% in the same period (P < 0.001). Phylogenic analysis of the ESBL and AmpC-β-lactamase-producers by pulsed-field gel electrophoresis and multi-locus sequence typing revealed wide genetic diversity even among the most common sequence type 11 isolates (33.0%). By multivariate analysis, later study year, elderly, and urine isolates were associated with carriage of ESBL genes, while only urine isolates were associated with carriage of AmpC β-lactamase genes. Further studies are needed to determine which antibiotics are reasonable empirical therapy options for patients presenting with severe sepsis that might be caused by K. pneumoniae.

show abstract

Section: Discussionmentioning

confidence: 99%

The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis

Lin

Wang

Chang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, AMP should be based on penicillins with BLIs, or first‐ or second‐generation cephalosporins (EL, IVa; RG, B). Because of the high prevalence of antimicrobial resistance, it has recently been recommended that penicillins without BLIs should not be prescribed for AMP . In addition, broad spectrum antimicrobials, such as third‐ and fourth‐generation cephalosporins, or carbapenems should be used for treatment of postoperative infections, but not for AMP (EL, IVa; RG, D).…”

Section: General Remarksmentioning

confidence: 99%

“…Because of the high prevalence of antimicrobial resistance, it has recently been recommended that penicillins without BLIs should not be prescribed for AMP. 5 In addition, broad spectrum antimicrobials, such as third-and fourth-generation cephalosporins, or carbapenems should be used for treatment of postoperative infections, but not for AMP (EL, IVa; RG, D). An adequate intratissue concentration of the antimicrobial at the surgical site should be accomplished by the time of initiation of surgery.…”

Section: Preoperative Management and Ampmentioning

confidence: 99%

Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition

Yamamoto

Shigemura

Kiyota³

et al. 2016

Int J of Urology

Self Cite

View full text Add to dashboard Cite

After publication of the initial version of the Japanese guidelines for urological surgery in 2007, new surgical techniques have been introduced. Furthermore, several important issues, such as criteria for use of single-dose antimicrobial prophylaxis and control of hospitalized infection, were also established, which led to alterations of the methods used for antimicrobial prophylaxis as well as perioperative management. The purpose of antimicrobial prophylaxis is to protect the surgical wound from contamination by normal bacterial flora. Antimicrobial prophylaxis should be based on penicillins with beta-lactamase inhibitors, or first-or second-generation cephalosporins, though penicillins without beta-lactamase inhibitors should not be prescribed because of the high prevalence of antimicrobial resistance. As an adequate intratissue concentration of the antimicrobial at the surgical site should be accomplished by the time of initiation of surgery, antimicrobial prophylaxis should be started up to 30 min before beginning the operation. Antimicrobial prophylaxis should be terminated within 24 h in clean and clean-contaminated surgery, and within 2 days of surgery using the bowels, because a longer duration is a risk factor for surgical site infection development. Importantly, possible risk factors for surgical site infections include the antimicrobial prophylaxis methodology used as well as others, such as duration of preoperative hospitalization, hand washing, the American Society of Anesthesiologists score, diabetes and smoking history. These guidelines are to be applied only for preoperatively non-infected low-risk patients. In cases with preoperative infection or bacteriuria that can cause a surgical site infection or urinary tract infection after surgery, patients must receive adequate preoperative treatment based on the individual situation.

show abstract

“…Most resistant bacteria gradually decreased over the three years examined except for QREC in the nationwide data. In Japan, the rates of QREC have been gradually increasing for several decades [18,19]. QREC may have emerged because of selective pressure imposed by the extensive use of oral fluoroquinolones [20,21].…”

Section: Discussionmentioning

confidence: 99%

Comparison between local and national epidemiology of antimicrobial resistance using the JANIS data

Takemura

Mochizuki

2018

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

The Japanese Ministry of Health, Labor and Welfare established the Japanese Nosocomial Infection Surveillance (JANIS) system in July 2000 to provide nationwide epidemiological information. The data of all clinically isolated bacteria at participating hospitals were collected, treated according to a protocol, and analyzed by the JANIS office. Nationwide and individual hospital data were reported to participating hospitals monthly and yearly. In this study, we surveyed local antimicrobial resistance of clinically isolated bacteria in Kawasaki City between 2014 and 2016 using JANIS data. There were 8, 14, and 16 major hospitals in Kawasaki City that participated in the surveillance in 2014, 2015, and 2016, respectively. The data were returned to each hospital monthly from JANIS, totaled for Kawasaki City, and compared with the nationwide data. The Kawasaki City data were approximately the same as the nationwide data, and most resistant bacteria decreased gradually over the three years examined. The incidence of methicillin-resistant Staphylococcus aureus (MRSA) in S. aureus (Kawasaki City, Japan) was (56.6%, 48.8%), (50.5%, 47.9%), and (51.6%, 46.9%), the incidence of penicillin-resistant Streptococcus pneumoniae (PRSP) in S. pneumoniae, was (43.4%, 37.5%), (34.3%, 38.0%), and (31.4%, 36.9%) in 2014, 2015, and 2016, respectively. Therefore, in Kawasaki City the incidence of MRSA was relatively higher and that of PRSP was relatively lower than the nationwide incidences. Both continuous local and national surveillance are important for monitoring antimicrobial resistance in clinical isolates. The JANIS database is a powerful tool for the epidemiology of nosocomial infections in Japanese hospitals.

show abstract

Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases

Cited by 28 publications

References 19 publications

The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis

The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis

Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition

Comparison between local and national epidemiology of antimicrobial resistance using the JANIS data

Contact Info

Product

Resources

About